BRCA2 and breast carcinoma: It is well‐known that breast cancer patients who carry germline mutations in either BRCA1 or BRCA2 are sensitive to PARP inhibitors.60 Although the OlympiAD trial only included patients with BRCA mutations, it was noteworthy that TNBC patients benefited more than those who were HR‐positive maybe due to the similarities in the gene‐expression profiles of BRCA1‐deficient breast cancers and sporadic TNBCs.49, 55 In addition, veliparib or iniparib + CT also showed superiority in PFS.